Bilateral primary breast Burkitt’s lymphoma in pregnancy

Abstract

Pregnancy-associated cancer is defined as malignancy diagnosed during gestation or up to 1 year post partum. Treatment of cancer during pregnancy is complicated by the risk of harm to the fetus and limitations in safety data. Postpartum patients receiving chemotherapy, tyrosine-kinase inhibitors or hormonal agents should avoid breast feeding to avoid drug excretion in breast milk. Patients who will receive cytotoxic chemotherapy should be advised of the potential impact on their future fertility and offered fertility-preservation options. Breast cancer is the most common pregnancy-associated malignancy and is most frequently either invasive ductal or lobular carcinoma. Breast lymphoma is an exceedingly rare diagnosis that typically presents with unilateral disease in the seventh decade of life. Here, we present the case of a woman who presented with bilateral breast masses during the second trimester of pregnancy and was ultimately diagnosed with primary breast Burkitt’s lymphoma.

MHIF-MSEA: a novel model of miRNA set enrichment analysis based on multi-source heterogeneous information fusion

“…Additionally, a study reported a case of basal cell carcinoma following radiotherapy for breast cancer in 2021 (Marques-Antunes et al, 2021). Moreover, the associations between breast cancer and pulmonary sarcoidosis, ischemic diseases, spinal cord injuries, Ewing's sarcoma and Lymphoma have been validated in the literature (Dong et al, 2021;Sawatzky et al, 2021;Altshuler et al, 2023). Collectively, these findings provide further confirmation of the MHIF-MSEA model's ability to accurately identify diseases that traditional enrichment analysis methods may overlook.…”